Senolytics, the case for clearing senescent cells

As we age, some cells stop dividing yet refuse to die. They linger in our tissues, release inflammatory signals, and accumulate over time. One line of research asks a simple question. What if we could selectively remove them? The compounds designed to do this are called senolytics, and they have become one of the most closely watched ideas in the biology of ageing. Here is what the approach involves, how it sits alongside related strategies, and what the evidence does and does not yet show.

The idea behind senolytics

Senolytics are compounds intended to selectively clear senescent cells, the lingering, non-dividing cells that build up in ageing tissue and quietly inflame their surroundings. The logic is straightforward. Senescent cells resist death through survival pathways that keep them alive far longer than a damaged cell would normally persist, and many of them secrete a mixture of inflammatory and tissue-remodelling signals. If these cells are a meaningful contributor to age-related decline, then removing them might restore some function. A 2022 review in the Journal of Clinical Investigation sets out the rationale for treating cellular senescence as a therapeutic target, drawing together the laboratory work that first suggested clearance could be beneficial.

Senolytics versus senomorphics

It helps to separate two distinct strategies that are often discussed together. Senolytics aim to kill senescent cells outright, typically by interfering with the anti-apoptotic pathways those cells rely on to stay alive. Senomorphics take a different route. Rather than removing the cell, they try to suppress its harmful secretions, quietening the inflammatory signalling without forcing the cell to die. A 2022 review in The FEBS Journal describes both classes under the broader heading of senotherapeutics and explains why each might be useful in different settings. The two approaches are not in competition so much as complementary, and a 2025 review in Biomolecules notes that the field is still working out where each is best suited.

The leading approaches studied

The senolytic combination that has attracted the most attention pairs a cancer medicine, dasatinib, with a plant compound, quercetin. The pairing was chosen because the two agents target different survival pathways, and using them together was intended to cover a wider range of senescent cell types than either alone. This combination has become the reference point for much of the early human work, and it is the example most often cited when senolytics are discussed. It is worth being clear that this is a research approach studied in trials, not an established treatment, and the details of how it might be used remain under investigation.

From mouse models toward early human trials

Much of the excitement around senolytics began in animals. In mouse studies, clearing senescent cells improved a range of age-related measures, and these results are what drove the field forward. Translating that to people is the harder step. A 2019 study published in EBioMedicine reported a first-in-human trial of dasatinib plus quercetin, and found that the combination reduced the number of senescent cells in treated participants. This was an early, small study, and its value lies less in any clinical outcome than in showing that the basic premise, that senescent cells can be measurably reduced in humans, holds up at all. The work since then has been about building on that proof of principle carefully.

The real caveats

Several genuine complications sit beneath the optimism. The first is heterogeneity. Senescent cells are strikingly varied, differing between tissues and between the triggers that produced them, which makes them hard to identify reliably and harder still to target precisely. A compound that clears one population may leave another untouched. The second is that senescence is not simply a fault to be removed. A 2024 article in Science emphasises that senescent cells have real physiological roles, contributing to wound healing and tissue repair, which means blunt, body-wide clearance is not obviously desirable. A 2022 review in Nature Reviews Clinical Oncology makes a related point in the context of cancer, where senescence can be protective in some settings and problematic in others. The third caveat is the simplest. The human evidence is still early, drawn from small studies, and far from the scale needed to draw firm conclusions.

What the evidence does and does not show

The honest summary is a measured one. The mechanistic case for senolytics is well developed, the animal evidence is substantial, and the first human studies suggest that senescent cells can be reduced in people. What the evidence does not yet show is that this translates into meaningful, durable benefits for health, nor how to do it safely across the many different senescent cell populations in the body. The heterogeneity of these cells, their useful roles, and the early stage of human research all argue for patience. This is one of the more promising directions in ageing biology, and it is a field to follow closely rather than a settled story. Nothing here is medical advice, and none of it points to a specific intervention anyone should act on today.

Further reading

Continue reading from the journal: Cellular senescence, explained in plain English and The hallmarks of cellular ageing, in plain English.

Sources

• Hickson LJ, et al. Senolytics decrease senescent cells in humans: first-in-human dasatinib plus quercetin trial. EBioMedicine, 2019. doi:10.1016/j.ebiom.2019.08.069
• Zhang L, Pitcher LE, Niedernhofer LJ, Robbins PD. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. The FEBS Journal, 2022. doi:10.1111/febs.16350
• Zhang L, et al. Cellular senescence as a therapeutic target. Journal of Clinical Investigation, 2022. doi:10.1172/JCI158450
• de Magalhães JP. Cellular senescence in normal physiology. Science, 2024. doi:10.1126/science.adj7050
• Schmitt CA, Wang B, Demaria M. Senescence and cancer, role and therapeutic opportunities. Nature Reviews Clinical Oncology, 2022. doi:10.1038/s41571-022-00668-4
• Saliev T, Singh PB. Senolytics and senomorphics review. Biomolecules, 2025. doi:10.3390/biom15060860